Insider

GSK plc

GSK Health Care · 2 analyses

Mentioned in recent filings: Ukraine Russia Tariffs Going-concern doubt

What changed

What changed

GSK receives recommendation for Bexsero booster dose

The European Medicines Agency recommended adding the option of a Bexsero vaccine booster dose for individuals aged 10 years and older. The change applies to patients who completed primary immunization at least two years earlier.

· GSK plc

Company history

October 2026

GSK plc: 12 recorded developments from 7 official sources in 2026-10.

  • 2026-09-22: An Independent Non-Executive Director purchased 936 Ordinary Shares of GSK plc at £18.8100 per share. Source
  • 2026-09-24: Maya Martinez-Davis, President, US, acquired notional ADS within her GSK Executive Supplemental Savings Plan account. Source
  • 2026-09-24: The transaction involved a price of $50.7200 and a volume of 9.414 American Depositary Shares (ADS). Source
  • 2026-09-24: The transaction is a single transaction with no aggregated volume or price information applicable. Source
  • 2026-10-01: The total number of voting rights figure may be used by shareholders as the denominator for calculations to determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparen Source
  • 2026-10-06: The notification covers the date range from 7 August 2026 to 2 October 2026 for the admission of securities to trading. Source
  • 2026-10-08: Wendy Becker, an independent Non-Executive Director of GSK plc, has been appointed as a Non-Executive Director of Tesco PLC with effect from 1 November 2026. Source
  • 2026-10-13: Acquisition of Ordinary Shares under the Company's Share Reward Plan at a price of £17.6539 for a volume of 7 (partnership shares) and £17.6539 for a volume of 7 (matching shares). Source
  • 2026-10-14: Shobie Ramakrishnan, Chief Digital and Technology Officer, has an interest in American Depositary Shares (‘ADS’) of GSK plc Source
  • 2026-10-14: David Redfern, President, Corporate Development, has an interest in Ordinary shares of 31 ¼ pence each (Ordinary Shares) of GSK plc Source
  • 2026-10-14: David Redfern, President, Corporate Development, increased notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan Source
  • 2026-10-14: Julie Brown acquired Ordinary Shares following the re-investment of dividends paid on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
GSK plc GSK———
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Large funds (13F)

FundSharesValueChange in sharesQuarter
Fidelity (FMR)64,920,926$3,127,240,971-0.1%Q3 2026
Wellington Management9,650,852$464,881,541-15.3%Q3 2026
State Street5,940,605$288,838,444-0.3%Q3 2026
BlackRock3,408,608$164,192,624-5.8%Q3 2026
D. E. Shaw & Co.1,954,472$94,146,916+91.7%Q3 2026
Citadel Advisors1,165,967$56,164,631+669.2%Q3 2026
Bridgewater Associates548,661$26,429,000+8.8%Q3 2026
Renaissance Technologies466,340$22,463,598+49.8%Q3 2026
Norges Bank (Norway's sovereign fund)200,000$10,484,000—Q2 2026
Two Sigma Investments186,489$8,983,175+162.7%Q3 2026
T. Rowe Price6,712,097$323,323-3.1%Q3 2026
Millennium Management4,067$224,458—Q1 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.